T cell costimulation blockade blunts pressure overload-induced heart failure

Area of Science:

• Cardiology
• Immunology
• Translational Medicine

Background:

• Heart failure (HF) is a major cause of death, with inflammation playing a key role.
• Previous trials targeting individual pro-inflammatory cytokines failed, suggesting complex inflammatory networks in HF.
• T cells are increasingly recognized as critical players in HF pathogenesis.

Purpose of the Study:

• To investigate the role of T cells in HF development.
• To evaluate the therapeutic potential of T cell costimulation blockade in a mouse model of HF.
• To explore the underlying mechanisms of T cell-mediated cardiac dysfunction.

Main Methods:

• Utilized a mouse model of pathological cardiac hypertrophy to induce HF.
• Administered abatacept, an FDA-approved T cell costimulation blocker.
• Assessed cardiac function, immune cell infiltration (T cells, macrophages), cardiomyocyte death, and cytokine profiles (including interleukin-10).
• Investigated the role of IL-10 and B cells in mediating therapeutic effects.

Main Results:

• Abatacept treatment significantly delayed HF progression and reduced cardiac dysfunction in mice.
• Therapeutic effects were associated with reduced T cell and macrophage activation and cardiac infiltration.
• Abatacept treatment decreased cardiomyocyte death and increased anti-inflammatory interleukin-10 (IL-10) production.
• IL-10-deficient mice did not respond to treatment, but protection was restored by IL-10-sufficient B cells.

Conclusions:

• T cell costimulation blockade, using abatacept, demonstrates significant therapeutic potential for HF.
• The mechanism involves suppressing detrimental T cell and macrophage activity and promoting an anti-inflammatory environment via IL-10.
• This study highlights T cell costimulation as a promising therapeutic target for managing heart failure.